Verana Health (San Francisco), which has expertise in turning clinical data into real-world evidence, announced today that it has inked a research collaboration agreement with Johnson & Johnson‘s Janssen Research & Development.
The research with Janssen will have an ophthalmology and urology focus.
In the ophthalmology space, Verana Health will analyze the American Academy of Ophthalmology’s IRIS registry data to characterize baseline patient attributes, disease progression, and treatment-based outcomes for people treated for diabetic macular edema, a complication of diabetes that impacts 750,000 Americans and may lead to severe vision loss.
The urology research will focus on early-stage prostate cancer. The first phase of the pilot will involve curating and evaluating de-identified data from a small subset of patients in the American Urological Association Quality (AQUA) registry.
“Characterizing early-stage prostate cancer has become increasingly important to improve patient outcomes. The ability to characterize early-stage urologic cancers is missing from many oncology databases, so we hope that Verana Health’s ability to fill this void can help thousands of men diagnosed with prostate cancer every year,” said Hylton Kalvaria, SVP of commercial and strategic partnerships for Verana Health.
Filed Under: Drug Discovery, Drug Discovery and Development
